A Phase 2 interventional study of LUM001 and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 3 sites in United Kingdom. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-28.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 2 that started in 2013, is one of 6 in phase 2, and was the 1st registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Belgium, France, Germany and 5 more countries
Ages 2 mo+
Mirum Pharmaceuticals, Inc. · Sites in United States
By country, each count listing its studies:
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 12 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2013.
This study's enrollment of 20 is below the median of 31 across 15 interventional studies indexed under Alagille Syndrome.
Median enrollment 31 across the 7 interventional studies, 47 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus placebo on the biochemical markers and pruritus associated with Alagille Syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM001 administered orally once each day
Drug: LUM001
Placebo administered orally once each day
Drug: Placebo
Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level
Participants were required to fast for at least 4 hours; only water was permitted prior to collection. A negative change from baseline indicates that the level of bile acid decreased.
Time frame: Baseline to 13 weeks or end of treatment
Change From Baseline to Week 13 (End of Treatment) in Liver Enzymes
Analysis of liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). A negative change from baseline indicates that the level of that enzyme decreased.
Time frame: Baseline to 13 weeks or end of treatment
Change From Baseline to Week 13 (End of Treatment) in Pruritus as Measured by The Patient And Observer Itch Reported Outcome (ItchRO) Average Daily Scores
The ItchRO was administered as a twice daily electronic diary (eDiary). Children ≥9 years of age completed the patient ItchRO; those between the ages of 5 and 8 completed the patient ItchRO with the assistance of their caregiver. There was no patient report for subjects under the age of 5. ItchRO scores range from 0 to 4, with the higher score indicating increasing itch severity. ItchRO average daily scores were calculated as the sum of daily scores (ie, the maximum of morning and evening scores) divided by the number of days. The average daily score was calculated by using the 7 days pre-treatment for baseline, and the last 7 days of treatment for Week 13. A negative change from Baseline indicates that itch severity decreased.
Time frame: Baseline to 13 weeks or end of treatment
| Milestone | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Cohort A | Placebo Cohort B |
|---|---|---|---|---|
| Started | 6 | 8 | 3 | 3 |
| Completed | 6 | 8 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 |
Participants were required to fast for at least 4 hours; only water was permitted prior to collection. A negative change from baseline indicates that the level of bile acid decreased.
| umol/L | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | LUM001 Overall | Placebo Overall |
|---|---|---|---|---|
| Change From Baseline to Week 13 (End of Treatment) in Fasting Serum Bile Acid Level | -82.864 ± 50.1513 | -49.388 ± 43.4732 | -66.126 ± 33.1208 | -42.157 ± 50.0903 |
Analysis of liver enzymes included alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP). A negative change from baseline indicates that the level of that enzyme decreased.
| U/L | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | LUM001 Overall | Placebo Overall |
|---|---|---|---|---|
| ALT | 59.3 ± 20.99 | 10.5 ± 18.06 | 34.9 ± 13.86 | 2.7 ± 21.06 |
| AST | 37.2 ± 13.64 | -2.7 ± 11.70 | 17.3 ± 8.98 | 13.2 ± 13.63 |
| ALP | 71.4 ± 53.35 | 31.6 ± 43.59 | 51.5 ± 36.13 | 19.7 ± 60.76 |
The ItchRO was administered as a twice daily electronic diary (eDiary). Children ≥9 years of age completed the patient ItchRO; those between the ages of 5 and 8 completed the patient ItchRO with the assistance of their caregiver. There was no patient report for subjects under the age of 5. ItchRO scores range from 0 to 4, with the higher score indicating increasing itch severity. ItchRO average daily scores were calculated as the sum of daily scores (ie, the maximum of morning and evening scores) divided by the number of days. The average daily score was calculated by using the 7 days pre-treatment for baseline, and the last 7 days of treatment for Week 13. A negative change from Baseline indicates that itch severity decreased.
| units on a scale | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | LUM001 Overall | Placebo Overall |
|---|---|---|---|---|
| Patient ItchRO | -1.159 ± 0.5396 | -0.608 ± 0.4399 | -0.883 ± 0.3484 | -0.811 ± 0.5684 |
| Observer ItchRO | -0.802 ± 0.2732 | -0.419 ± 0.2318 | -0.610 ± 0.1776 | -0.592 ± 0.2690 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM001 140ug/kg/Day | — | 0/6 (0%) | 6/6 (100%) |
| LUM001 280ug/kg/Day | — | 0/8 (0%) | 7/8 (87.5%) |
| Placebo Overall | — | 0/6 (0%) | 4/6 (66.7%) |
| Event | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Overall |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 4/6 | 5/8 | 2/6 |
| Abdominal painGastrointestinal disorders | 1/6 | 5/8 | 1/6 |
| Upper respiratory tract infectionInfections and infestations | 3/6 | 1/8 | 3/6 |
| NasopharyngitisInfections and infestations | 2/6 | 1/8 | 1/6 |
| HeadacheNervous system disorders | 2/6 | 1/8 | 0/6 |
| VomitingGastrointestinal disorders | 0/6 | 2/8 | 1/6 |
| Anal injuryInjury, poisoning and procedural complications | 0/6 | 2/8 | 0/6 |
| Deafness unilateralEar and labyrinth disorders | 1/6 | 0/8 | 0/6 |
| Ear painEar and labyrinth disorders | 1/6 | 0/8 | 0/6 |
| Middle ear inflammationEar and labyrinth disorders | 1/6 | 0/8 | 0/6 |
All randomized participants
| Age, Continuous(years) | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Cohort A | Placebo Cohort B | Total |
|---|---|---|---|---|---|
| Mean | 5.8 ± 4.49 | 6.8 ± 6.73 | 5.0 ± 2.00 | 4.3 ± 3.21 | 5.9 ± 4.93 |
| Age, Customized(participants) | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Cohort A | Placebo Cohort B | Total |
|---|---|---|---|---|---|
| < 2 years | 0 | 3 | 0 | 0 | 3 |
| 2 to 4 years | 3 | 1 | 1 | 2 | 7 |
| 5 to 8 years | 1 | 1 | 2 | 1 | 5 |
| 9 to 12 years | 2 | 0 | 0 | 0 | 2 |
| 13 to 18 years | 0 | 3 | 0 | 0 | 3 |
| Sex: Female, Male(Participants) | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Cohort A | Placebo Cohort B | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 3 | 2 | 10 |
| Male | 4 | 5 | 0 | 1 | 10 |
| Region of Enrollment(participants) | LUM001 140ug/kg/Day | LUM001 280ug/kg/Day | Placebo Cohort A | Placebo Cohort B | Total |
|---|---|---|---|---|---|
| United Kingdom | 6 | 8 | 3 | 3 | 20 |
The record gives a start of Aug 2013, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat